Compare BridgeBio Pharma Inc (BBIO) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Cassava Sciences Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: BridgeBio Pharma Inc is far larger — about 342.6× Cassava Sciences Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | FLNA | |
|---|---|---|
Market Cap | $16.36B | $47.75M |
Sector | Health | Health |
52-Week High | $90.17 | $4.64 |
52-Week Low | $47.29 | $0.87 |
Enterprise Value | $18.14B | -$34.93M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
